EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Alpelisib-Induced Diabetic Ketoacidosis and Insulin-Resistant Hyperglycemia

Michael Loke, Vishal Sehgal, Niraj Gupta

AACE Clinical Case Reports · 2025-01 · 11 (1) · 40-44

DOI: 10.1016/j.aace.2024.10.002 ↗

Kurz gefasst

Fallbericht in der Zeitschrift AACE Clinical Case Reports, 2025-01. Verfasst von Michael Loke und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ascension St. Vincent Internal Medicine, Indianapolis, Indiana. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objective: Alpelisib is a phosphatidylinositol 3-kinase inhibitor used to treat certain hormone therapy resistant breast cancers that can cause hyperglycemia through inhibition of the insulin signaling cascade. Diabetic ketoacidosis with the initiation of alpelisib remains a rare complication. The objective of this report is to describe a patient with alpelisib-induced diabetic ketoacidosis and the difficulties of management. Case Report: A 59-year-old woman was admitted to the hospital with a history of noninsulin dependent type 2 diabetes on metformin presented with diabetic ketoacidosis. One month prior to this hospitalization, the patient was started on alpelisib. On presentation, blood glucose level was 612 mg/dL and hemoglobin A1c level was 11.9% (107 mmol/mol), a 4.6% (27 mmol/mol) increase from 2 months prior. The patient was started on intravenous insulin and alpelisib was held resulting in rapid resolution of the patient's hyperglycemia and ketoacidosis. However, with reinitiation of alpelisib the patient developed worsening hyperglycemia. Relative glycemic control was ultimately obtained with 3 oral agents and high doses of insulin.

Discussion

Direct inhibition of insulin signaling by alpelisib leads to insulin-resistant hyperglycemia. Most cases can be controlled with oral agents; however, insulin therapy is required in rare instances. Although more effective for glycemic control, insulin therapy has the potential to decrease the antitumor effects of alpelisib.

Conclusion

Diabetic ketoacidosis is a rare complication of alpelisib initiation, which is quickly resolved with cessation of the agent. For patients where cessation is not an option, insulin and insulin sensitizing agents can be used to achieve glycemic control at the potential detriment of tumor treatment.

Schlagwörter

Stichwörter der Autor:innen

PI3K inhibitoralpelisibdiabetic ketoacidosisresistant hyperglycemia

Autor:innen und Institutionen

  • Ascension St. Vincent Internal Medicine, Indianapolis, Indiana.
  • Ascension St. Vincent Endocrinology, Indianapolis, Indiana.
  • Ascension St. Vincent Hematology and Oncology, Indianapolis, Indiana.

Zitieren

APA

Loke, M., Sehgal, V., & Gupta, N. (2025). Alpelisib-Induced Diabetic Ketoacidosis and Insulin-Resistant Hyperglycemia. AACE Clinical Case Reports, 11(1), 40-44. https://doi.org/10.1016/j.aace.2024.10.002

Vancouver

Loke M, Sehgal V, Gupta N. Alpelisib-Induced Diabetic Ketoacidosis and Insulin-Resistant Hyperglycemia. AACE Clinical Case Reports. 2025;11(1):40-44. doi:10.1016/j.aace.2024.10.002

BibTeX
@article{Loke2025,
  author = {Loke, Michael and Sehgal, Vishal and Gupta, Niraj},
  title = {Alpelisib-Induced Diabetic Ketoacidosis and Insulin-Resistant Hyperglycemia},
  journal = {AACE Clinical Case Reports},
  year = {2025},
  volume = {11},
  number = {1},
  pages = {40--44},
  doi = {10.1016/j.aace.2024.10.002}
}
Kostenlos starten →